Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

Zepbound (tirzepatide) combines a GLP-1 and GIP in a single molecule which enhances the effects of increased satiety and slowing of gastric emptying. Clinical researchers studying the efficacy of ...

Although tirzepatide use was associated with elevated amylase and lipase levels, risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss. New research findings of its effect on ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

A long-term study reveals how tirzepatide not only cuts weight but also slashes diabetes risk in people with prediabetes, highlighting a major advance in obesity and diabetes care. In a phase-3 ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...